Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AbbVie Inc.

NYSE

Market Cap.

277.35B

Avg. Volume

5.63M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze AbbVie Inc.!

Still processing it, give me a bit more time...

AbbVie Inc. News

AbbVie Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
abbvie.com

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. Earnings & Revenue

AbbVie Inc. Financials

Table Compare

Compare ABBV metrics with:

   

Earnings & Growth

ABBV

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ABBV

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ABBV

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ABBV

None

Debt Ratio

--

--

Quick Ratio

--

--

 

AbbVie Inc. Income

AbbVie Inc. Balance Sheet

AbbVie Inc. Cash Flow

AbbVie Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsBuy
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

AbbVie Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

6.0600

Payment DateDividendFrequency
2024-05-151.55Quarterly
2024-02-151.55Quarterly
2023-11-151.48Quarterly
2023-08-151.48Quarterly
2023-05-151.48Quarterly

Historical Market Cap

Shares Outstanding

AbbVie Inc. Executives

NameRole
Mr. Richard A. GonzalezChairman & Chief Executive Officer
Mr. Robert A. MichaelPresident & Chief Operating Officer
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial Officer
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer
Mr. Scott T. ReentsExecutive Vice President & Chief Financial Officer
NameRoleGenderDate of BirthPay
Mr. Richard A. GonzalezChairman & Chief Executive OfficerMale19547.19M
Mr. Robert A. MichaelPresident & Chief Operating OfficerMale19704.62M
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial OfficerMale19694.32M
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer19633.51M
Mr. Scott T. ReentsExecutive Vice President & Chief Financial OfficerMale19683.13M

AbbVie Inc. Insider Trades

Date3 May
NameDavis Jennifer L.
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameQuaggin Susan E
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameRAPP EDWARD J
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameAlpern Robert J
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameFREYMAN THOMAS C
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
DateNameRoleTransactionTypeShares
3 MayDavis Jennifer L.DirectorAcquiredA-Award1322
3 MayQuaggin Susan EDirectorAcquiredA-Award1322
3 MayRAPP EDWARD JDirectorAcquiredA-Award1322
3 MayAlpern Robert JDirectorAcquiredA-Award1322
3 MayFREYMAN THOMAS CDirectorAcquiredA-Award1322

Discover More

Streamlined Academy

AbbVie Inc.

NYSE

Market Cap.

277.35B

Avg. Volume

5.63M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AbbVie Inc. News

AbbVie Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

AbbVie Inc. Earnings & Revenue

AbbVie Inc. Income

AbbVie Inc. Balance Sheet

AbbVie Inc. Cash Flow

AbbVie Inc. Financials Over Time

AbbVie Inc. Executives

NameRole
Mr. Richard A. GonzalezChairman & Chief Executive Officer
Mr. Robert A. MichaelPresident & Chief Operating Officer
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial Officer
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer
Mr. Scott T. ReentsExecutive Vice President & Chief Financial Officer
NameRoleGenderDate of BirthPay
Mr. Richard A. GonzalezChairman & Chief Executive OfficerMale19547.19M
Mr. Robert A. MichaelPresident & Chief Operating OfficerMale19704.62M
Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial OfficerMale19694.32M
Dr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating Officer19633.51M
Mr. Scott T. ReentsExecutive Vice President & Chief Financial OfficerMale19683.13M

AbbVie Inc. Insider Trades

Date3 May
NameDavis Jennifer L.
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameQuaggin Susan E
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameRAPP EDWARD J
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameAlpern Robert J
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
Date3 May
NameFREYMAN THOMAS C
RoleDirector
TransactionAcquired
TypeA-Award
Shares1322
DateNameRoleTransactionTypeShares
3 MayDavis Jennifer L.DirectorAcquiredA-Award1322
3 MayQuaggin Susan EDirectorAcquiredA-Award1322
3 MayRAPP EDWARD JDirectorAcquiredA-Award1322
3 MayAlpern Robert JDirectorAcquiredA-Award1322
3 MayFREYMAN THOMAS CDirectorAcquiredA-Award1322

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
abbvie.com

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze AbbVie Inc.!

Still processing it, give me a bit more time...

AbbVie Inc. Financials

Table Compare

Compare ABBV metrics with:

   

Earnings & Growth

ABBV

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ABBV

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ABBV

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ABBV

None

Debt Ratio

--

--

Quick Ratio

--

--

 

AbbVie Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

6.0600

Payment DateDividendFrequency
2024-05-151.55Quarterly
2024-02-151.55Quarterly
2023-11-151.48Quarterly
2023-08-151.48Quarterly
2023-05-151.48Quarterly

AbbVie Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsBuy
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More